The study is an open-label, single arm, multicenter, Phase III study to determine proteinuria reduction, pharmacokinetics (PK), safety and tolerability (includ…

Primary Immunoglobulin A Nephropathy (IgAN)

~Estimated

~$10 – $8,750

Novartis PharmaceuticalsNCT06994845

Phase 3

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Felzartamab in Adults With IgA Nephropathy (PREVAIL)

In this study, researchers will learn more about the use of felzartamab in participants with immunoglobulin A nephropathy (IgAN). IgAN is a kidney disease caus…

Immunoglobulin A Nephropathy (IgAN)

An Open-label, Multicenter Study to Assess the Effect of Zigakibart Treatment on Histologic, Circulating, and Excreted Markers of Kidney Disease and Dysfunction in Adult Patients With IgA Nephropathy.

The purpose of the study is to assess the effect of zigakibart on IgA nephropathy (IgAN) disease progression.

Immunoglobulin A Nephropathy (IgAN)

~Estimated

~$10 – $8,750

Novartis PharmaceuticalsNCT07146906